PE-22-28 Dosage Guide: Protocols, Calculator & Safety

A defensible beginner protocol for PE-22-28 starts with explicit acknowledgment of the limitations of the evidence base. This is a peptide with a small number of preclinical studies, no human clinical trials, and widespread but uncontrolled use in biohacker communities. A beginner should enter use with realistic expectations (effects may or may not be noticeable; benefits if present may be subtle; adverse effects are possible), a plan for monitoring (mood tracking, sleep tracking, objective or semi-objective assessments of mood and cognition), and a willingness to stop if the experiment does not produce useful information. A conservative beginner dose range from self-report community reports is 250-500 micrograms per injection administered subcutaneously, dosed daily or every other day. These doses are empirical rather than clinically validated. Beginners should start at the low end (250 mcg daily) and hold at the starting dose for at least 2-3 weeks before any titration, to allow time for early effects to emerge. Cycle duration for beginners is typically 4-6 weeks of continuous daily or every-other-day dosing, followed by a break of at least 2-4 weeks before any repeat cycle. The break provides time for any transient effects to wash out and for subjective and objective markers to return to baseline, providing a cleaner read on whether the compound produced durable changes. Route of administration for self-experimenters is overwhelmingly subcutaneous, using insulin syringes (28-31 gauge, 0.3-0.5 mL capacity) into abdominal subcutaneous fat, thigh, or upper arm. Subcutaneous dosing is the safest route for self-administration and provides adequate bioavailability for peptide dosing. Timing of administration within the day is typically morning, though there is no strong pharmacokinetic basis for specific timing; some users prefer afternoon dosing if they find the peptide to produce subjective sedation. Monitoring during a beginner cycle should focus on the outcomes the user is actually interested in. For depression applications, standardized mood scales (PHQ-9 for depression, GAD-7 for anxiety) provide a quantitative baseline and can be repeated weekly during the cycle to track changes. Keeping a daily mood and symptom log with specific items (sleep quality, energy level, motivation, appetite, anxiety level, irritability, cognitive clarity) provides richer information than a global subjective impression. For cognitive applications, standardized cognitive assessments (Cambridge Brain Sciences, DANTE, or similar online tools) provide objective performance metrics. For general wellness applications, the tracking can be less formal but should include at minimum a weekly check-in with oneself about whether the cycle is producing noticeable effects. Labs for a beginner PE-22-28 cycle are less critical than for metabolic compounds because the peptide is not expected to produce significant changes in standard blood panels. A baseline CBC, CMP, and thyroid panel are reasonable to rule out underlying conditions that might confound interpretation. For users with specific concerns (cardiovascular disease, autoimmune conditions, complex psychiatric history), additional baseline labs may be indicated. Decision framework after one beginner cycle: if the cycle produced clearly adverse effects (worsening mood, anxiety escalation, persistent physical symptoms, unusual injection site reactions), stop and do not continue; if the cycle produced no detectable effects on the tracking metrics you prioritized, reconsider whether continued use is justified — PE-22-28 is not cheap, and if it does nothing for you, continuing to inject it is not rational; if the cycle produced a coherent pattern of subjective or objective improvements in mood or cognition, cautious continuation with additional cycles is reasonable while maintaining monitoring. A specific caution for depression applications: significant depression is a serious medical condition that warrants evaluation by a mental health professional, and self-treatment with a research-chemical peptide without professional support is not an adequate approach to clinical depression. Users experiencing significant depression symptoms should seek professional care. Users with milder or subclinical mood complaints who are curious about peptide approaches have a different risk profile but should still maintain adequate self-monitoring and be prepared to seek professional care if their condition worsens. The beginner protocol specifically avoids the mistake of using PE-22-28 as the primary approach to managing clinical depression, which would be inappropriate regardless of any compound's mechanism of action.

Intermediate users have completed a beginner cycle or two with real tracking and are considering longer cycles, somewhat higher doses, or combinations. A typical intermediate approach uses roughly 500-1000 micrograms per injection, subcutaneously, daily or every other day, in 6-8 week cycles with 2-4 week breaks. The higher dose assumes beginner doses may be subtherapeutic - an empirical guess, not a validated fact, and one to weigh against the fact that rodent efficacy occurred at far lower microgram-per-kilogram doses.

Combinations are common at this stage, most often with other neuro-peptides such as Selank or Semax, or with general-purpose peptides like BPC-157. Each addition makes it harder to attribute any effect to PE-22-28 specifically, so add one compound at a time. Monitoring should extend beginner practice: standardized mood and, if relevant, cognitive assessments at baseline, mid-cycle and end-of-cycle, plus objective sleep tracking with a wearable, since sleep is often the first thing a mood-active compound changes. Baseline and end-of-cycle bloodwork (CBC, CMP) is reasonable general diligence rather than a response to any known PE-22-28 toxicity.

This is also where honest self-assessment matters most. Subjective impressions, placebo and expectancy effects, and normal week-to-week mood variation are easy to mistake for drug effects. Cost is real too: research-chemical PE-22-28 typically runs tens of dollars per vial, and multi-week cycles add up across a year once labs and any stacked compounds are included. If cycles are not producing clear benefit on the outcomes you actually care about, the disciplined response is to stop - not to escalate dose or pile on compounds, which is the most common self-experimentation error. And PE-22-28 should never become a substitute for evidence-based care for clinical depression; anyone with a significant psychiatric history should have a clinician involved.

Advanced PE-22-28 use is the domain of experienced self-experimenters who have already run structured cycles with real tracking and understand that they are working far ahead of the evidence. Community "advanced" dosing pushes to roughly 1000-2000 micrograms per injection, daily or every other day, in 8-12 week cycles with multi-week breaks. There is no clinical evidence that higher doses do more than increase exposure and cost - and given that rodent efficacy occurred at microgram-per-kilogram doses, escalating into the milligram range is extrapolation, not optimization.

At this level the real questions are about integration and monitoring rather than dose. PE-22-28 is an antidepressant-candidate TREK-1 blocker, so it is most coherently framed as the mood-directed element of a stack, sometimes combined with other neuro-peptides community users favor for anxiolytic or cognitive effects (for example Selank or Semax). Every added compound loses attribution and stacks risk, so a disciplined user adds one thing at a time. Stacking PE-22-28 with its own parent peptide spadin is redundant, and there is no basis for framing it as a mitochondrial or general "cytoprotective" agent - that is a different class of peptide entirely.

Monitoring should be genuinely rigorous: standardized mood scales (PHQ-9, GAD-7) at baseline and through each cycle, objective sleep and activity tracking, and periodic bloodwork (CBC, CMP, and any condition-specific markers) - not because PE-22-28 is known to perturb them, but to catch anything unexpected. Anyone with a meaningful psychiatric history needs a mental-health professional involved; self-monitoring does not replace that. Advanced users should pre-commit to stop criteria (clear adverse effects, or simply no benefit on the outcomes they care about) and to a de-escalation plan, because the sophistication of a protocol does not compensate for the absence of any human validation. If it is not clearly helping, the rational move is to stop, not to escalate.